Skip to main content

Patrick Ellsworth, MD

Assistant Professor, Division of Hematology

Specialty Areas:

Non-malignant hematology, primarily bleeding disorders and sickle cell disease.


Fellow, University of North Carolina Hospitals, Medical Hematology, July 2017 – June 2020
Fellow, University of North Carolina Hospitals, Pediatric Hematology and Oncology, July, 2016 – June 2020
Resident, University of Rochester Medical Center, Internal Medicine and Pediatrics, July, 2012 – June 2016
MD, The Ohio State University College of Medicine, Columbus, OH, June 2012
BA, German, Cum Laude, University of Utah. Salt Lake City, UT, August 2008

Research Interests:

I am active in developing and using microfluidic, in vitro models to investigate the role of coagulation proteins in the interaction of blood cells and endothelial cells. Working in the lab of Nigel Key, I have participated in research investigating the role that coagulation proteins play in the pathophysiology of sickle cell disease. I am especially interested in the interaction of von Willebrand Factor with red blood cells in sickle cell disease, and whether we can develop systems to predict and evaluate patient response to emerging therapies for this disorder.

Using these in vitro assays, I am also working with Dr. Mac Monroe to explore the mechanism of thrombosis in patients receiving emicizumab, a novel, non-factor therapy for persons with Hemophilia A.

I am also interested clinically in how to better treat bleeding episodes in patients with acquired and inherited bleeding disorders, as these present a particular challenge to patients and providers.  Finally, I actively participate in quality improvement efforts to standardize and optimize the transition of care for patients with non-malignant hematologic disorders from pediatric to adult care.

Awards and Grants:

UNC Benign Hematology T32 Grant recipient (2018-2020)
NHF-Takeda Clinical Fellowship Award recipient (2020-Present)


Ellsworth P, Chen SL, Key N, Abajas Y, Ma A. Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy [published online ahead of print, 2020 Aug 25]. Haemophilia. 2020;10.1111/hae.14111. doi:10.1111/hae.14111

Ellsworth P, Chen S, Key NS, Kasthuri RS, Mooberry MJ, and Ma AD. Recombinant Porcine FVIII for Bleed Treatment in Acquired Hemophilia A: Findings from a Single-Center, 18 Patient Cohort. Manuscript in revision.

Wilson S, Ellsworth P, Key NS. Pregnancy in sickle cell trait: what we do and don’t know. Br J Haematol. 2020;190(3):328-335. doi:10.1111/bjh.16518

Sparkenbaugh EM, Kasztan M, Henderson MW, Ellsworth P, Davis PR, Wilson KJ, Reeves B, Key NS, Strickland S, McCrae K, Pollock DM, Pawlinski R.High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease [published online ahead of print, 2020 Jun 23]. J Thromb Haemost. 2020;10.1111/jth.14972. doi:10.1111/jth.14972

Noubouossie DF, Henderson MW, Mooberry M, Ilich A, Ellsworth P, Piegore M, Skinner SC, Pawlinski R, Welsby I, Renné T, Hoffman M, Monroe DM, Key NS. Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood. 2020;135(10):755-765. doi:10.1182/blood.2019001643

Faes C, Ilich A, Sotiaux A, Sparkenbaugh EM, Henderson MW, Buczek L, Beckman JD, Ellsworth P, Noubouossie DF, Bhoopat L, Piegore M, Renoux C, Bergmeier W, Park Y, Ataga KI, Bolley B, Wolberg AS, Key NS, Pawlinski R. Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood [In Press]


  • Address

    116 Manning Drive


    Chapel Hill, NC 27514